
Pakistani woman deported after Pahalgam attack to get visitor's visa: MHA to J&K HC
The bench further noted that Rashid can pursue the two applications moved by her regarding acquiring Indian citizenship as well as a long-term visa.The court recorded the submission of the solicitor general and noted that "once an in-principle decision is taken by the competent authority, there is hardly any doubt that, post compliance of the requisite procedures and formalities, the authority would process and accord a visitor's visa to the respondent at the earliest".The court dismissed Rashid's writ petition seeking relief from the deportation, saying that as a natural consequence, the impugned interim order loses its relevance and thus ceases to exist and operate.On July 22, Mehta requested the court to defer the proceedings to enable him to explore whether the respondent could be helped in any manner or if it was still feasible to address her concerns.In response, Rashid's counsel, Ankur Sharma and Himani Khajuria, submitted that she was agreeable to the course suggested by the solicitor general.On June 6, a single-judge bench of Justice Rahul Bharti ordered the Central government to "retrieve" Rashid.While passing the order, Justice Bharti observed, "This court is bearing in mind the background reference that the petitioner was having long-term visa (LTV) status at the relevant point of time, which per se may not have warranted her deportation, but without examining her case in a better perspective and coming up with a proper order with respect to her deportation from the authorities concerned, she came to be forced out." Rashid was served with a Leave India Notice on April 28 under Sections 3(1), 7(1), and 2(c) of the Immigration and Foreigners Act, 1946, issued by the Criminal Investigation Department, directing her to leave the country by or before April 29.She approached the high court and sought interim relief to stay the operation of the order.However, she was issued an exit permit and escorted to the Attari-Wagah border in Amritsar by the authorities, from where she crossed over to Pakistan.Rashid, a resident of Jammu's Talab Khatikan area, has four children who continue to reside in Jammu and Kashmir.Rashid, daughter of Mohammad Rashid from Namuddin Road in Islamabad, entered India on February 10, 1990, via Attari on a 14-day visitor visa to visit Jammu.She continued to stay under an LTV granted by the authorities on an annual basis. During her stay, she revealed that she married an Indian national."It wasn't disputed either that her LTV was valid up to January 13, 2025, and she had applied for an extension on January 4, 2025. But no such extension was ever accorded," the order noted.Her husband expressed happiness over the decision and thanked the court.
"We are relieved... The entire family was under tension. We were suffering due to the decision (to deport her)," he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
19 minutes ago
- Business Standard
US tariffs should not be cause for disengaging from trade talks, blocs
The fundamental challenge for the Indian economy is to increase productivity and competitiveness premium Business Standard Editorial Comment Mumbai Listen to This Article The tariff rate of 25 per cent, which United States (US) President Donald Trump has decided will be applied to Indian exports to the US, may not, eventually, be the final rate. It may effectively wind up being higher if he carries out his threat to add a surcharge related to India's increasing purchases of Russian oil. It may be lower if New Delhi's negotiators pull some sort of a broader deal together. It is also worth remembering that there will be multiple exceptions to this headline tariff rate. Some goods that compose a large part of India-US trade —


News18
29 minutes ago
- News18
Following are the top foreign stories at 2100 hours
FGN6 BANGLA-HASINA ****Bangladesh tribunal commences trial of deposed PM Hasina over crimes against humanity Dhaka: Bangladesh's International Crimes Tribunal (ICT) on Sunday commenced the trial of deposed Prime Minister Sheikh Hasina in absentia over crimes against humanity related to the violent suppression of the 2024 student-led protests.**** FGN17 BANGLA-RALLIES ****B'desh: BNP's student wing, NCP hold rallies ahead of July Uprising anniversary Dhaka: Activists of the National Citizen Party and the BNP's student wing held separate rallies in Bangladesh on Sunday ahead of the first anniversary of the July Uprising that toppled the Sheikh Hasina-led government on August 5 last year.**** FGN9 PAK-IRAN-NUCLEAR ****Pakistan supports Iran's right to develop nuclear capability for peaceful purposes Islamabad: Pakistan on Sunday supported Iran's right to develop nuclear capability for peaceful purposes, as the two sides signed several agreements to expand cooperation in multiple fields.**** FGN8 PAK-IRAN-TRADE ****Pakistan: Iran decide to increase bilateral trade to USD 8 billion annually Islamabad: Pakistan and Iran agreed on Sunday to increase bilateral trade to USD 8 billion annually, taking advantage of their geography and the 'discount of distance," as trade ministers from the two countries held discussions to deepen economic and political ties.**** FGN14 US-INDIANS-ACCIDENT ****Four senior Indian-origin persons killed in car crash in West Virginia New York: In a tragic incident, four senior Indian-origin persons were killed in a car crash in West Virginia, authorities said on Sunday.


India Today
35 minutes ago
- India Today
How Trump tariffs could impact Indian pharma's $8.7 bn dream run
For long, the high-value US market has driven the growth of the storied Indian generic drugs industry, where companies like Cipla, Sun Pharma and Dr Reddy's Laboratories, among others, have successfully challenged hundreds of off-patent drugs in the US and established a soaring business FY24, India exported $8.7 billion (Rs 76,113 crore) worth of pharma products to the US, which comprises over 11 per cent of India's total merchandise exports to that the same period, India exported $77.5 billion (Rs 6.8 lakh crore) worth of merchandise goods to the US and imported $42.2 billion (Rs 3.7 lakh crore) worth of goods from it, resulting in a trade surplus of $35.3 billion (Rs 3 lakh crore) in India's US is India's largest destination for pharma exports, accounting for over 31 per cent of the country's total pharmaceutical exports. As much as 47 per cent of all generics consumed in the US are imported from India. However, the Donald Trump administration's threat of imposition of a 25 per cent reciprocal tariff from August 1 (up from 0 to 6.7 per cent at present) has thrown the Indian pharma industry in a bind. Shares of Indian pharma companies, led by Sun Pharma, fell close to 6 per cent on the NSE (National Stock Exchange) on August 1 following president Trump's statements on the tariff imposition, and his letters to 17 top US pharma companies asking them to reduce their rates in line with what prevailed in other countries. Some fear Trump may send a similar letter to Sun Pharma, which earns as much as 20 per cent of its total revenues from the US Indian industry was hoping against hope that Trump would not hike tariffs on generic drugs since these are life-saving. However, Trump had indicated earlier this year too that tariffs on pharma products would be 25 per cent from April 2 onwards, without pinpointing any nation. He later gave a 90-day reprieve to countries, and the new deadline for the tariffs was put as August imports roughly $800 million worth of pharmaceutical products from the US, and imposes a tariff of 10 per cent. Experts say that even if higher tariffs are imposed on active pharma ingredients (APIs), which are raw materials going into pharma production, India could still be competitive, if tariffs on other API-supplying countries are higher than that of the US will still be dependent on countries like India since the cost of manufacturing certain drugs in the US would be at least six times compared to that of manufacturing the same product in India, say industry US market, which relies heavily on India for APIs and low-cost generics, would struggle to find alternatives, according to Namit Joshi, chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India). 'Efforts to shift pharmaceutical manufacturing and API production to other countries or within the US will take at least 3-5 years to establish meaningful capacity,' he was quoted in media reports. advertisement'There is no need for panic. The industry should lie low for now since the US has not yet increased the tariffs. Who else can give the US such competitively-priced goods in large quantities and high quality?' Daara Patel, secretary general of the Indian Drug Manufacturers Association, had said in an interview to INDIA TODAY in April. 'Even if it increases up to 10 per cent, the industry should be able to absorb it or pass it on to the US consumers. They would not mind paying for it since it all works on insurance money,' he what if the US decides to go for a higher tariff? 'In case the US raises tariffs beyond 15 per cent, India will have to look at newer markets in East Africa and the Middle East. These markets are neither high value nor high in volumes, but it will be a better option than dealing with an uncertain US market alone,' Patel had saidSubscribe to India Today Magazine- EndsTune InMust Watch